Novartis is eking out the life of its aging immunology med, Cosentyx, with another label expansion.
The anti-IL-17 just became the first in its lass to be approved by the FDA for patients with polymyalgia rheumatica (PMR) who can’t take or don’t respond to corticosteroids.
An inflammatory disease common in adults over 50, PMR affects nearly 1 million Americans, by Novartis estimates, and causes acute pain and stiffness in the shoulders, neck and hips. Steroids are the current standard of care, but 40% of patients continue to relapse within the first year of treatment and long-term steroid use comes with serious side effects.
In the phase 3 Replenish trial, Novartis compared two doses of Cosentyx, 300 mg and 150 mg, to placebo. All three treatment groups were combined with a 24-week steroid taper. At one year, the study met its primary endpoint with patients on 150 mg of Cosentyx achieving sustained remission at nearly twice the rate of placebo, 40.5% versus 20.5%, respectively.
The safety profile was in line with previous Cosentyx trials; patients on Cosentyx experienced an increased amount of eczema, dermatitis, rash and urticaria as well as urinary tract infections (UTI). There was also a serious UTI and fatal case of cryptococcal meningitis in the Cosentyx group.
“For too long, treatment options beyond glucocorticoids have been limited,” said John Stone, M.D., of Harvard Medical School and global principal investigator for the Replenish trial.
The label expansion lands as Cosentyx’s core patent is set to expire in the U.S. in 2029 with EU expiration soon after in 2030. Label expansion is one of Novartis’ key tactics to weather price erosion, both from pending biosimilar entry and ongoing competition from next-generation immunology drugs like IL-23s, which have already overtaken Cosentyx in its inaugural indication of psoriasis.
Despite its many challengers, Cosentyx’s current performance remains strong, helping Novartis offset the losses of older blockbusters like Entresto. In 2025, Cosentyx brought in $6.7 billion in revenue, and so far in 2026, the drug’s nine-month revenue was up 8% over last year, reaching $5.2 billion. The boost was largely driven by uptake in spondyloarthritis and hidradenitis suppurativa, two indications where Cosentyx doesn’t face the weight of IL-23 competition.
“For more than a decade, Cosentyx has helped redefine what’s possible for people living with immune-mediated diseases, delivering meaningful outcomes across multiple conditions,” Victor Bultó, president of Novartis’ U.S. business, said in a Nov. 17 statement. “With this approval in PMR, our 11th U.S. indication for Cosentyx, we are expanding those benefits to a community that has had limited treatment options for far too long. This milestone reflects our commitment to continually investigate where our medicines can help patients most, extending the impact of proven innovations to new areas of significant unmet need.”